Literature DB >> 11019706

Owner assessment of the outcome of total hip arthroplasty in dogs.

C T Skurla1, E L Egger, P D Schwarz, S P James.   

Abstract

OBJECTIVE: To evaluate owners' perceptions of the outcomes of dogs that have undergone total hip arthroplasty (THA).
DESIGN: Survey. SAMPLE POPULATION: Owners of 145 dogs that had undergone THA. PROCEDURE: Surveys were mailed to owners of 353 dogs that underwent THA between 1982 and 1996. Owners were asked to answer multiple-choice questions and provide written comments.
RESULTS: The response rate was 41%. For owners who responded to the survey, time from surgery to completion of the questionnaire ranged from 6 months to 11 years. Overall, 122 respondents (84.1%) rated results of THA in their dog as excellent or good. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that owners are generally satisfied with the results of THA in their dogs.

Entities:  

Mesh:

Year:  2000        PMID: 11019706     DOI: 10.2460/javma.2000.217.1010

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  3 in total

1.  Modular hybrid total hip arthroplasty. Experimental study in dogs.

Authors:  Bruno W Minto; Cláudia Valéria S Brandão; Gilberto J C Pereira; Daniela Campagnol; Maria Jaqueline Mamprim; Carlos Roberto Padovani; José J T Ranzani
Journal:  Acta Vet Scand       Date:  2011-07-07       Impact factor: 1.695

2.  Evaluation of ranges of motion of a new constrained acetabular prosthesis for canine total hip replacement.

Authors:  Ching-Ho Wu; Cheng-Chung Lin; Tung-Wu Lu; Sheng-Mao Hou; Chih-Chung Hu; Lih-Seng Yeh
Journal:  Biomed Eng Online       Date:  2013-11-10       Impact factor: 2.819

3.  Greater trochanter morphology and association with patient demographics, surgical factors, and post-operative stem position: a retrospective assessment of 150 cementless THRs in 135 dogs.

Authors:  Catrina J Silveira; Katherine H Barnes; Sharon C Kerwin; W Brian Saunders
Journal:  BMC Vet Res       Date:  2022-02-23       Impact factor: 2.741

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.